Peter Marks

NEW YORK — Her voice sounded tight, anxious, tinged with pain. "I was, you know, underneath one of them while the two laughed," the actress Elizabeth Marvel recited.

Desdemona. Hedda Gabler. Jean Brodie. Professor McGonagall. Violet Crawley. The prime of Dame Maggie Smith seemed never-ending.

Optimizing analytics, including laser force cytology, with a goal to delivering adaptive manufacturing, full automation and standardized processes, products and patient outcomes.

Repairing nucleotide abnormalities for rare disease populations as pivotal proving grounds for transformative therapies.

Standardization leading to CGT therapies becoming a standard of care. Importance to outcomes of high-quality starting materials, to reducing batch-to-batch quality, and the possibilities of allogeneic chimeric antigen receptor therapy (CAR-T) successes.

Looking ahead 5-10 years for in vivo practice. Combined platform and modalities marriages, to bring CGT up to first relapse or consolidation therapies.

Popular new delivery vectors, and some not fully appreciated like Non-AAV parvoviruses or Herpes Simplex virus. Are we in a transition state, where there is a growing a trend away from Viral Vectors? How do we best regulate CRISPR?

Addressing manufacturing at scale for ATMP's. Reducing costs through reducing batch failures and shrinking footprints, and targeting more focused critical quality attributes for potency but also patient efficacy. Reducing regulatory uncertainty in an uncertain environment to increase patient access to life saving cures.

Success and Challenges (Potholes) in Cell and Gene Therapy: automation, regulatory certainty, and standardizing manufacture processes such as vector constructs or Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) steps.

Senior Pharma and Biotech Leaders to Gather the Weekend Immediately Prior to JP Morgan Healthcare Conference for 2 Day Networking Forum, San Francisco CEO, Hosted by Longwood Healthcare Leaders